Adaptimmune Therapeutics
ADAP
ADAP was delisted on the 27th of October, 2025.
79 hedge funds and large institutions have $1.04B invested in Adaptimmune Therapeutics in 2020 Q3 according to their latest regulatory filings, with 23 funds opening new positions, 23 increasing their positions, 19 reducing their positions, and 20 closing their positions.
95% more call options, than puts
Call options by funds: $2.02M | Put options by funds: $1.04M
21% more repeat investments, than reductions
Existing positions increased: 23 | Existing positions reduced: 19
15% more first-time investments, than exits
New positions opened: 23 | Existing positions closed: 20
3% more funds holding
Funds holding: 77 → 79 (+2)
1.02% more ownership
Funds ownership: 82.09% → 83.11% (+1%)
19% less capital invested
Capital invested by funds: $1.28B → $1.04B (-$248M)
50% less funds holding in top 10
Funds holding in top 10: 4 → 2 (-2)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Baillie Gifford & Co
Edinburgh,
United Kingdom
|
+$15.7M |
| 2 |
Citadel Advisors
Miami,
Florida
|
+$14.9M |
| 3 |
Victory Capital Management
San Antonio,
Texas
|
+$8.81M |
| 4 |
ACA
Avoro Capital Advisors
New York
|
+$8.75M |
| 5 |
PHS
PFM Health Sciences
San Francisco,
California
|
+$7.43M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
RCM
RA Capital Management
Boston,
Massachusetts
|
-$15.1M |
| 2 |
ACP
Acuta Capital Partners
Redwood City,
California
|
-$11.7M |
| 3 |
Millennium Management
New York
|
-$9.48M |
| 4 |
VA
VR Adviser
New York
|
-$7.83M |
| 5 |
Marshall Wace
London,
United Kingdom
|
-$3.77M |
ADAP Hedge Fund Activity: Q3 2020 in Review
79 of the 4,970 institutional investors tracked by Wall St. Rank reported a position in Adaptimmune Therapeutics (ADAP) for Q3 2020, worth a combined $1.04B — down 19% from $1.28B a quarter earlier.
Buyers outnumbered sellers: 23 funds opened new ADAP positions and 20 closed out — a net gain of 3 holders — while 23 added to existing stakes and 19 trimmed.
The largest buyer was Baillie Gifford & Co, adding an estimated $15.7M. The largest seller was RA Capital Management, cutting an estimated $15.1M.
- 79 institutional investors held Adaptimmune Therapeutics (ADAP) as of Q3 2020, up from 77 in Q2 2020.
- Funds reported $1.04B of Adaptimmune Therapeutics stock for Q3 2020, down 19% quarter-over-quarter.
- 23 funds opened new Adaptimmune Therapeutics positions in Q3 2020 and 20 closed out, a net change of +3 holders.
- The largest Adaptimmune Therapeutics buyer in Q3 2020 was Baillie Gifford & Co, an estimated $15.7M added.
- The largest Adaptimmune Therapeutics seller in Q3 2020 was RA Capital Management, an estimated $15.1M sold.
Based on aggregated 13F filings for Q3 2020.